Literature DB >> 7884579

Widespread tissue distribution of human chymase.

H Urata1, F Strobel, D Ganten.   

Abstract

OBJECTIVE: Human chymase is a potent and specific angiotensin (Ang) II-forming serine proteinase. Although the histological localization of heart chymase indicated that this enzyme contributes to extracellular Ang II formation, the systemic distribution and the level of expression of chymase in various human tissues have not been clarified. This information is needed to elucidate the human tissue Ang II system.
METHODS: Levels of immunoreactivity and enzymatic activity in various human tissues were evaluated respectively by Western blot analysis and by an enzymatic assay for Ang II-forming activity from Ang I.
RESULTS: High levels of chymase-like immunoreactivity were found in alimentary tract tissue, uterus and tonsil; moderate levels were found in both cardiac ventricles, lung, adenoid and liver; low levels were found in the cardiac atria, coronary artery, aorta and skin; and almost undetectable levels were found in the spleen and kidney. High levels of chymase-like enzymatic activity were detected in skin, oesophagus, stomach and uterus; moderate levels were found in both cardiac ventricles, lung, colon, tonsil, adenoid and renal cortex; and low levels were found in the cardiac atria, coronary artery, aorta, spleen, renal medulla and liver.
CONCLUSIONS: Our studies have revealed heterogeneous and widespread tissue distribution of human chymase throughout the human body and indicate that chymase probably has a significant influence not only in the heart but also in other tissues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884579

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  13 in total

Review 1.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 2.  Should we aim at tissue renin-angiotensin systems?

Authors:  J F Smits; R C Passier; M J Daemen
Journal:  Pharm World Sci       Date:  1998-06

3.  A novel vascular smooth muscle chymase is upregulated in hypertensive rats.

Authors:  C Guo; H Ju; D Leung; H Massaeli; M Shi; M Rabinovitch
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 4.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

Review 5.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

Review 6.  Pathologic consequences of increased angiotensin II activity.

Authors:  C M Ferrario; J M Flack
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

Review 7.  What is the role of renin inhibition in the treatment of diabetic kidney disease?

Authors:  Radko Komers
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

8.  Pathogenesis of atherosclerosis: A multifactorial process.

Authors:  Raja B Singh; Sushma A Mengi; Yan-Jun Xu; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2002

9.  Mechanical induction of an epithelial cell chymase associated with wound edge migration.

Authors:  James D Firth; Veli-Jukka Uitto; Edward E Putnins
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

10.  Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

Authors:  C Malerczyk; B Fuchs; G G Belz; S Roll; R Butzer; K Breithaupt-Grögler; V Herrmann; S G Magin; A Högemann; B Voith; E Mutschler
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.